Interstitial Lung Disease Induced by Pazopanib Treatment-Reference-Cited by-同舟云学术

Interstitial Lung Disease Induced by Pazopanib Treatment

Published:2017 Issue:1 Volume:56 Page:79-83
ISSN:0918-2918
Container-title:Internal Medicine
language:en
Short-container-title:Intern. Med.

Author:

Ide Shotaro¹²,Sakamoto Noriho¹,Hara Shintaro¹,Hara Atsuko¹,Kakugawa Tomoyuki¹,Nakamura Yoichi¹,Futsuki Yoji³,Izumikawa Koichi²,Ishimatsu Yuji⁴,Yanagihara Katsunori⁵,Mukae Hiroshi¹

Affiliation:

1. Department of Respiratory Medicine, Unit of Translational Medicine, Nagasaki University Graduate School of Biomedical Sciences, Japan

2. Department of Infectious Diseases, Unit of Molecular Microbiology and Immunology, Nagasaki University Graduate School of Biomedical Sciences, Japan

3. Department of Respiratory Medicine, Saiseikai Nagasaki Hospital, Japan

4. Department of Health Sciences, Unit of Rehabilitation Sciences, Nagasaki University Graduate School of Biomedical Sciences, Japan

5. Department of Laboratory Medicine, Unit of Translational Medicine, Nagasaki University Graduate School of Biomedical Sciences, Japan

Publisher

Japanese Society of Internal Medicine

Subject

General Medicine,Internal Medicine

Link

https://www.jstage.jst.go.jp/article/internalmedicine/56/1/56_56.7380/_pdf

Reference20 articles.

1. 1. Schutz FA, Choueiri TK, Sternberg CN. Pazopanib: clinical development of a potent anti-angiogenic drug. Crit Rev Oncol Hematol 77: 163-171, 2011.

2. 2. Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 28: 1061-1068, 2010.